Arbutus Short Long Term Debt vs Total Stockholder Equity Analysis
| ABUS Stock | USD 2.73 0.01 0.37% |
Arbutus Biopharma financial indicator trend analysis is way more than just evaluating Arbutus Biopharma Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Arbutus Biopharma Corp is a good investment. Please check the relationship between Arbutus Biopharma Short Long Term Debt and its Total Stockholder Equity accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment.
Short Long Term Debt vs Total Stockholder Equity
Short Long Term Debt vs Total Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Arbutus Biopharma Corp Short Long Term Debt account and Total Stockholder Equity. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Arbutus Biopharma's Short Long Term Debt and Total Stockholder Equity is 0.42. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Total Stockholder Equity in the same time period over historical financial statements of Arbutus Biopharma Corp, assuming nothing else is changed. The correlation between historical values of Arbutus Biopharma's Short Long Term Debt and Total Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Arbutus Biopharma Corp are associated (or correlated) with its Total Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Stockholder Equity has no effect on the direction of Short Long Term Debt i.e., Arbutus Biopharma's Short Long Term Debt and Total Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.42 |
| Relationship Direction | Positive |
| Relationship Strength | Weak |
Short Long Term Debt
The total of a company’s short-term and long-term borrowings.Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Most indicators from Arbutus Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Arbutus Biopharma Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. At this time, Arbutus Biopharma's Issuance Of Capital Stock is comparatively stable compared to the past year. Sales General And Administrative To Revenue is likely to gain to 2.32 in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.
Arbutus Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Arbutus Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Arbutus Biopharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 105.5M | 137.1M | 204.5M | 195.4M | 144.4M | 124.4M | |
| Other Current Liab | 253K | 250K | 26K | 12.5M | 7.0M | 3.8M | |
| Total Current Liabilities | 7.8M | 9.5M | 11.2M | 32.9M | 22.5M | 23.6M | |
| Total Stockholder Equity | 72.7M | 102.0M | 169.4M | 136.9M | 106.0M | 93.5M | |
| Property Plant And Equipment Net | 11.4M | 9.3M | 8.1M | 6.8M | 6.1M | 4.8M | |
| Net Debt | (28.4M) | (49.3M) | (106.7M) | (28.6M) | (17.6M) | (18.4M) | |
| Retained Earnings | (970.1M) | (1.0B) | (1.1B) | (1.2B) | (1.3B) | (1.2B) | |
| Cash | 31.8M | 52.3M | 109.3M | 30.8M | 26.3M | 39.9M | |
| Non Current Assets Total | 11.7M | 9.4M | 43.8M | 44.3M | 12.4M | 11.8M | |
| Non Currrent Assets Other | 293K | 44K | 61K | 103K | 92.7K | 88.1K | |
| Cash And Short Term Investments | 90.8M | 123.3M | 155.3M | 146.9M | 126.0M | 73.6M | |
| Net Receivables | 1.2M | 4.4M | 5.3M | 4.2M | 2.4M | 1.8M | |
| Common Stock Total Equity | 898.5M | 985.9M | 1.3B | 1.3B | 1.5B | 1.6B | |
| Common Stock Shares Outstanding | 57.1M | 75.8M | 106.2M | 150.9M | 166.0M | 174.3M | |
| Short Term Investments | 59.0M | 71.0M | 46.0M | 116.1M | 99.7M | 104.7M | |
| Liabilities And Stockholders Equity | 105.5M | 137.1M | 204.5M | 195.4M | 144.4M | 124.4M | |
| Non Current Liabilities Total | 25.0M | 25.6M | 23.8M | 25.7M | 15.9M | 25.0M | |
| Other Current Assets | 1.8M | 3.1M | 4.4M | 2.9M | 3.6M | 3.8M | |
| Other Stockholder Equity | 55.2M | 60.8M | 65.5M | 72.4M | 81.3M | 78.5M | |
| Total Liab | 32.8M | 35.1M | 35.0M | 58.6M | 38.4M | 31.0M | |
| Property Plant And Equipment Gross | 11.4M | 9.3M | 8.1M | 6.8M | 18.0M | 18.9M | |
| Total Current Assets | 93.8M | 127.7M | 160.7M | 151.1M | 132.0M | 76.6M | |
| Common Stock | 898.5M | 985.9M | 1.3B | 1.3B | 1.3B | 1.4B | |
| Other Liab | 21.9M | 23.0M | 21.6M | 23.9M | 27.5M | 18.6M | |
| Net Tangible Assets | (64.5M) | (47.4M) | 169.4M | 136.9M | 157.4M | 165.2M | |
| Accounts Payable | 2.4M | 3.0M | 3.2M | 3.5M | 3.2M | 2.5M | |
| Retained Earnings Total Equity | (970.1M) | (1.0B) | (1.1B) | (1.2B) | (1.1B) | (1.0B) | |
| Preferred Stock Total Equity | 49.8M | 126.1M | 137.3M | 149.4M | 171.8M | 180.4M | |
| Accumulated Other Comprehensive Income | (48.2M) | (48.2M) | (48.3M) | (50.5M) | (48.4M) | (46.0M) | |
| Property Plant Equipment | 8.7M | 6.9M | 6.0M | 5.1M | 5.8M | 4.5M | |
| Capital Surpluse | 55.2M | 60.8M | 65.5M | 72.4M | 83.3M | 53.5M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Arbutus Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Arbutus Biopharma's short interest history, or implied volatility extrapolated from Arbutus Biopharma options trading.
Pair Trading with Arbutus Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Arbutus Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Arbutus Biopharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Arbutus Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Arbutus Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Arbutus Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Arbutus Biopharma Corp to buy it.
The correlation of Arbutus Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Arbutus Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Arbutus Biopharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Arbutus Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arbutus Biopharma Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Arbutus Stock analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |
Is Arbutus Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arbutus Biopharma. If investors know Arbutus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arbutus Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Revenue Per Share 0.109 | Quarterly Revenue Growth (0.66) | Return On Assets (0.29) | Return On Equity (0.60) |
The market value of Arbutus Biopharma Corp is measured differently than its book value, which is the value of Arbutus that is recorded on the company's balance sheet. Investors also form their own opinion of Arbutus Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Arbutus Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arbutus Biopharma's market value can be influenced by many factors that don't directly affect Arbutus Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arbutus Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Arbutus Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arbutus Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.